Inhibrx Biosciences (INBX) Assets Average (2024 - 2026)
Inhibrx Biosciences (INBX) posted quarterly Assets Average of $162.0 million for Q4 2025, down 19.68% year-over-year from $201.7 million in Q4 2024, and down 16.85% quarter-over-quarter from $194.8 million in Q3 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Assets Average (2024 - 2026) Analysis & Trends
Inhibrx Biosciences (INBX) has reported Assets Average for 2 consecutive years, with $162.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average fell 19.68% year-over-year to $162.0 million; the TTM figure through Dec 2025 stood at $162.0 million (down 19.68% YoY), while the FY2025 annual figure was $163.6 million, down 33.03% from the prior year.
- Assets Average fell to $162.0 million in Q4 2025 per INBX's latest filing, from $194.8 million in the prior quarter.
- Across five years, Assets Average topped out at $240.5 million in Q3 2024 and bottomed at $162.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - | 150.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 150.35 Mn |
| Dec 31, 2025 | 161.97 Mn |
| Sep 30, 2025 | 194.79 Mn |
| Jun 30, 2025 | 227.38 Mn |
| Mar 31, 2025 | 211.70 Mn |
| Dec 31, 2024 | 201.66 Mn |
| Sep 30, 2024 | 240.49 Mn |